ClinicalTrials.gg
CompletedNCT01068964Updated Apr 17, 2019Results posted

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

An interventional study of 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution and 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution in Open-angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.

Enrollment
12th of 29
235 · median 169
Started
2010
with 4 others
No phase
Only one
of the 29
Registered
2nd of 29
by date
Lead sponsor
17 of 29
Allergan

Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is the only one with no phase, and was the 2nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimatoprost

Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing bimatoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily administered 0.5% Timolol Ophthalmic Solution concurrently in patients with open-angle glaucoma or ocular hypertension

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of open-angle glaucoma or ocular hypertension in one or both eyes
  • Eye pressure lowering topical medications are not working
  • Visual acuity is at least 0.2 in each eye

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Any other active eye disease other than glaucoma or ocular hypertension
  • Significant visual field loss or evidence of progressive visual field loss within the last year
  • Anticipated wearing of contact lenses during the study
  • Required chronic use of other ocular medications during the study
  • Eye surgery or laser treatment within 12 weeks prior to study enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    0.03% Bimatoprost/0.5% Timolol in Same Bottle

    Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution

    Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution

  • Active comparator
    0.03% Bimatoprost and 0.5% Timolol in Separate Bottles

    Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution

    Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution

Interventions

  • Drug0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution

    Drug pages: Bimatoprost · Timolol

    One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution

    Also known as: Bottle 1: Ganfort®

  • Drug0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution

    Drug pages: Bimatoprost Ophthalmic Solution · Timolol

    One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution

    Also known as: Bottle 1: Lumigan®, Bottle 2: Timoptol®

06

What researchers measure

Primary outcomes

  1. The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4

    The difference of change from baseline of mean diurnal IOP between the 0.03% Bimatoprost/0.5% Timolol in Same Bottle and the 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles at week 4. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of the study eye (the eye with the highest IOP at baseline) over the 3 time points measured at 8AM, 12PM and 4PM. A negative number change from baseline indicated a reduction (improvement) in IOP. The difference of change from baseline in IOP is presented in the statistical analysis section.

    Time frame: Baseline, Week 4

07

Results

Posted Jan 20, 2012

Participant flow

Participant flow — Overall Study
Milestone0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate Bottles
Started121114
Completed113104
Not completed810

Outcome measures

PrimaryThe Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4

The difference of change from baseline of mean diurnal IOP between the 0.03% Bimatoprost/0.5% Timolol in Same Bottle and the 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles at week 4. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of the study eye (the eye with the highest IOP at baseline) over the 3 time points measured at 8AM, 12PM and 4PM. A negative number change from baseline indicated a reduction (improvement) in IOP. The difference of change from baseline in IOP is presented in the statistical analysis section.

Time frame:
Baseline, Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4
Millimeters of mercury (mmHg)0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate Bottles
Baseline25.20 ± 3.0624.87 ± 3.88
Change from Baseline at Week 4-9.38 ± 4.66-8.93 ± 4.25
Statistical analysis
  • 0.03% Bimatoprost/0.5% Timolol in Same Bottle vs 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles · Mean difference (final values): -0.556 · 95% CI -1.68 to 0.57

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.03% Bimatoprost/0.5% Timolol in Same Bottle—0/121 (0%)30/121 (24.8%)
0.03% Bimatoprost and 0.5% Timolol in Separate Bottles—2/114 (1.8%)29/114 (25.4%)
Most frequent serious events
Most frequent serious events
Event0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate Bottles
GoitreEndocrine disorders0/1211/114
Ocular hypertensionEye disorders0/1211/114
Most frequent other events
Most frequent other events
Event0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate Bottles
Conjunctival hyperaemiaEye disorders26/12121/114
Eye painEye disorders4/1218/114

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate BottlesTotal
Mean45.73 ± 14.7744.28 ± 16.2845.02 ± 15.51
Sex: Female, Male
Sex: Female, Male(Participants)0.03% Bimatoprost/0.5% Timolol in Same Bottle0.03% Bimatoprost and 0.5% Timolol in Separate BottlesTotal
Female464692
Male7568143
08

Study locations

1 site
  • Beijing, China
09

References and documents

Publications

  • Ling Z, Zhang M, Hu Y, Yin Z, Xing Y, Fang A, Ye J, Chen X, Liu D, Wang Y, Sun W, Dong Y, Sun X. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chin Med J (Engl). 2014;127(5):905-10. PubMed 24571886 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Sep 2010, 7 months.

Results were first posted in Jan 2012, 1 year 4 months after primary completion.

Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 7 months is below that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2010
First posted
Feb 17, 2010
StartActual
Feb 1, 2010
Primary completionActual
Sep 1, 2010
CompletionActual
Sep 1, 2010
Results first posted
Jan 20, 2012
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01068964
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 17, 2010
Start date
Feb 1, 2010
Primary completion
Sep 1, 2010
Completion
Sep 1, 2010
Results posted
Jan 20, 2012
Last update
Apr 17, 2019

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimatoprost · Timolol

Start the discussion